batanopride has been researched along with Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Osoba, D; Pater, J; Rusthoven, J; Slamet, L; Warr, D; Zee, B | 1 |
| Aapro, M; Alberts, D; Brady, M; Comerski, C; Dorn, M; Fairchild, C; Plezia, P; Sartiano, G; Schwartz, SE; Smaldone, L | 1 |
2 review(s) available for batanopride and Neoplasms
| Article | Year |
|---|---|
Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Doxorubicin; Female; Granisetron; Humans; Male; Methylprednisolone; Metoclopramide; Middle Aged; Nausea; Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Serotonin Antagonists; Treatment Outcome; Vomiting | 1994 |
Batanopride (BMY-25801): a new 5-HT3 receptor antagonist for the prevention of cancer chemotherapy-induced emesis.
Topics: Animals; Antiemetics; Antineoplastic Agents; Cisplatin; Dogs; Dopamine Antagonists; Female; Ferrets; Hemodynamics; Humans; Male; Metoclopramide; Mice; Middle Aged; Neoplasms; Rats; Serotonin Antagonists; Vomiting | 1990 |
1 trial(s) available for batanopride and Neoplasms
| Article | Year |
|---|---|
Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Doxorubicin; Female; Granisetron; Humans; Male; Methylprednisolone; Metoclopramide; Middle Aged; Nausea; Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Serotonin Antagonists; Treatment Outcome; Vomiting | 1994 |